Journal
CLINICAL IMMUNOLOGY
Volume 161, Issue 1, Pages 2-10Publisher
ACADEMIC PRESS INC ELSEVIER SCIENCE
DOI: 10.1016/j.clim.2015.04.005
Keywords
Rheumatoid arthritis; Psoriatic arthritis; Biomarkers; Autoantibodies; Synovial tissue biomarkers; Serological biomarkers
Categories
Funding
- Dutch Arthritis Foundation [31308]
- Netherlands Organization for Scientific Research
- IMI JU funded project BeTheCure [115142-2]
- Health Research Board, Ireland [R12983, R13798]
- ZON-MW Vidi [016.126.334]
- Janssen Biologics [QBS11031FELLUMC]
Ask authors/readers for more resources
Rheumatic diseases, such as rheumatoid and psoriatic arthritis are systemic inflammatory conditions characterized by a chronic form of arthritis, often leading to irreversible joint damage. Early treatment for patients with rheumatic diseases is required to reduce or prevent joint injury. However, early diagnosis can be difficult and currently it is not possible to predict which individual patient will develop progressive erosive disease or who may benefit from a specific treatment according to their clinical features at presentation. Biomarkers are therefore required to enable earlier diagnosis and predict prognosis in both rheumatoid arthritis and psoriatic arthritis. In this review we will examine the evidence and current status of established and experimental biomarkers in rheumatoid and psoriatic arthritis for three important purposes; disease diagnosis, prognosis and prediction of response to therapy. (C) 2015 Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available